TRIDOPA levodopa/carbidopa/entacapone 100/25/200 mg tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 100/25/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

TRIDOPA levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: magnesium stearate; powdered cellulose; sodium sulfate; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 50/12.5/200 levodopa 50 mg, carbidopa (as carbidopa monohydrate) 12.5 mg and entacapone 200 mg film-coated tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 50/12.5/200 levodopa 50 mg, carbidopa (as carbidopa monohydrate) 12.5 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose; mannitol; titanium dioxide; magnesium stearate; povidone; maize starch; sucrose; iron oxide red; glycerol; iron oxide yellow; polysorbate 80; croscarmellose sodium - l.c.e. sandoz 50/12.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

SINADOPA 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sinadopa 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; indigo carmine aluminium lake; crospovidone - sinadopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. sinadopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

STALEVO 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

stalevo 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 100 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 175 mg; carbidopa monohydrate, quantity: 47.2 mg (equivalent: carbidopa, qty 43.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 125 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; allura red ac aluminium lake; carmine - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.